Research & Development: Page 45
-
PharmaVoice Team/PharmaVoice
HealthTech
Blood Test Uses Machine Learning to Detect Multiple Early-Stage Cancers Trend Watch: Digital therapeutics, chips, patches, and machine learning enable better health outcomes. Johns Hopkins Kimmel Cancer Center researchers developed a single blood test — CancerSEEK, a unique noninvasive, multi-ana...
By PharmaVoice Team • March 1, 2018 -
PharmaVoice Team/PharmaVoice
Addressing Diversity in Clinical Trials
Eliminating health disparities is an important public health issue, concerning all stakeholders. In oncology, for example, there are five cancers where disparities in adults have been identified: prostate cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, and multiple myeloma. Fo...
By Denise Myshko • March 1, 2018 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Speak Out
From Discovery to Clinical Practice: A Brand Journey Requires Connected Thinking Today’s pharmaceutical brands are on the journey of a lifetime. And throughout this journey a brand takes on a burgeoning number of data sets, from pre-clinical trials all the way to real-world evidence and populat...
By Louisa Holland • March 1, 2018 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Using Stem Cells to Treat Frailty Longeveron’s Chief Science Officer and Co-Founder Dr. Joshua Hare talks about the company’s cell-based therapies for age-related diseases. Breakthroughs in stem cell research could potentially lead to new treatment options for chronic diseases and injuries affec...
By Dr. Joshua Hare • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
HealthTech
Draper R&D Uses Technology to Solve Unmet Healthcare Needs Trend Watch: Health technology is providing quicker, safer solutions for disease management and care. Draper, a nonprofit research and development company focused on advanced technological solutions, has designed the first pediatric h...
By PharmaVoice Team • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
Last Word
Connecting Silos Through System Integration Monica Kennedy, Director of Regulatory Operations at Halozyme, discusses how technology can be leveraged to address inefficiencies in organizations. PV: What do think has led to operational silos and created inefficiencies? Kennedy: Technology is one f...
By Monica Kennedy • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
Patient-Centric Trial Recruitment
Social media, mobile, and other technologies are making patient and physician outreach easier and more cost-effective and analytical tools are enhancing performance measurement, but patient recruitment for clinical trials continues to be a challenge. This is especially true for trials involving r...
By Denise Myshko • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Outsourcing: The Growth and Expansion of Outsourcing
Outsourcing in the pharma industry continues to increase, with many companies spending $50 million or more a year on outsourcing services. A survey from Outsourcing-Pharma.com found that 44% of pharmaceutical companies expected to outsource more business in 2017 than the previous year, and only 1...
By PharmaVoice Team • Feb. 1, 2018 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Tired of “innovation“ yet? No doubt that innovation is one of those “buzz-tion" words — transformation, collaboration, disruption — that some might deride as having been used so frequently that it has lost some of its inherent value as an action-based, momentum-driving movement. I say nay. Innova...
By Taren Grom • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Next-Generation Immuno-Oncology Stephen Isaacs, President and CEO of Aduro Biotech, talks about the company’s research of a small molecule that acts as a personalized “vaccine" against cancer. In recent years, we have seen the development and approval of immuno-oncology therapies that increase ...
By Stephen Isaacs • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
HealthTech
Apple Watch Expands Capabilities to improve health outcomes in cardiac, diabetes, depression Trend Watch: Apple Watch continues to revolutionize health data collection. Did you get an Apple Watch for the holidays? Lucky you, especially since several additional capabilities were unveiled at the en...
By PharmaVoice Team • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Pharma Innovation Labs
Innovative or collaborative partnerships in pharma are being touted by some as the “new normal." Certainly, this is true of several pioneering pharmaceutical companies in the space, but authentic, independent or open-source collaborations are still a minority in the life-sciences ecosystem. The b...
By Robin Robinson • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Next-Generation Nanomedicines
The first generation of nanotechnology-based medicines, including nano-based drug delivery systems and nanovectors, improved the safe delivery of therapies that were once toxic. Nanoparticles have also proven to be especially good vehicles to effectively deliver cancer drugs, where many therapies...
By Denise Myshko • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Women's Healthcare: Drug Development
With a U.S. healthcare market estimated at $2.8 trillion and purchasing either made or largely influenced by women, the “power of the purse" has never been stronger. According to Carolyn Buck Luce, executive-in-residence at the Center for Talent Innovation and an adjunct professor at Columbia Uni...
By Taren Grom • Jan. 1, 2018 -
PharmaVoice Team/PharmaVoice
Trend Tracking
In this special — 2018 Year in Preview — issue, PharmaVOICE’s thought leaders are tackling 10 trends that are expected to incite change in the year ahead. We will be looking at a variety of disparate topics that range from molecule to market in keeping with our publishing focus and philosophy: 20...
By Taren Grom • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Trending 2018: Real-World Outcomes
Real-word outcomes is not a new trend by any means, but it’s a market-changing model that is coming into its own and worthy of covering. That’s because the pharmaceutical market continues to shift to an outcomes-based reimbursement system, driven by payers’ need to rein in rising drug prices, adv...
By Denise Myshko • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Picture This: Managing the Entire Lifecycle of Clinical Trial Images in a Single Tool
One of the great promises of technology is that it can simplify our lives. The need for it to do so is particularly strong in clinical research, where trials have been growing ever more complex. This is due, in part, to regulators’ increasing requests for the inclusion of imaging analysis when ev...
By Tim Kulbago • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Speak Out
Innovations in Alzheimer’s Clinical Trial Design Promise to Reduce Time, Risk by Allison House, Therapeutic Strategy Lead, Neuroscience, Worldwide Clinical Trials and Natalia Drosopoulou, Senior Director, Global Project Management, Neuroscience, Worldwide Clinical Trials The global impact of Alz...
By Allison House • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Red Zone: Innovation in Hematopoietic Cell Transplantation and Gene and Cellular Therapies Drive Results in Pediatric Oncology
This is an exciting time in medicine, providing more novel treatments for patients with cancer blood disorders. Scientists are learning more about the human genome and its role in disease. This knowledge allows investigators to develop new diagnostic tools and therapeutic interventions to more sp...
By Medpace • Nov. 20, 2017 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Connected Health At this month’s 2017 Connected Health Conference to be held in Boston, industry leaders will gather to discuss a multitude of topics that are focused on improving health outcomes by accelerating the adoption of personal connected health. A couple of the major themes to be discuss...
By Taren Grom • Oct. 1, 2017 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Using Electric Fields to Treat Cancer Bill Doyle, Executive Chairman of Novocure, talks about the company’s treatment that uses electric fields to treat glioblastoma, a deadly brain cancer, and other cancers. Novocure’s approach to treating cancer may look like pseudo science, but the results are...
By Bill Doyle • Oct. 1, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
Pharma’s Role in the Community John Damonti, President of the Bristol-Myers Squibb Foundation and VP of Corporate Philanthropy at Bristol-Myers Squibb, talks about how his company and other pharmaceutical companies can provide relief during disasters, such as Hurricanes Harvey and Irma. PV: Why d...
By John Damonti • Oct. 1, 2017 -
PharmaVoice Team/PharmaVoice
A Connected Healthcare Life
Three years ago, Verily — then a division of Google X — unveiled its Baseline Project, a collaboration with Duke University and Stanford University to collect health data from healthy people to get a sense of what “normal" looks like. Earlier this year, the group began the process of enrolling 10...
By Robin Robinson • Oct. 1, 2017 -
PharmaVoice Team/PharmaVoice
Solutions for Clinical Sites
Clinical study sites are transforming their technology infrastructures with the adoption of electronic medical records (EMRs). But while EMRs improve treatment-related tasks in healthcare settings, they have not helped to reduce the burden of clinical trial studies on the sites. A May 2017 survey...
By Denise Myshko • Oct. 1, 2017 -
PharmaVoice Team/PharmaVoice
Upfront
Bayer and the White Ribbon Alliance The partnership of Bayer and the White Ribbon Alliance (WRA), Every Woman Every Child, has reached 1,200 women in 91 communities across four developing countries. The partnership’s goal has been to launch local community programs to support the reduction and pr...
By PharmaVoice Team • Sept. 1, 2017
Previous
